Vanguard Group Inc. Grows Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Vanguard Group Inc. increased its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 7.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,906,764 shares of the company's stock after buying an additional 641,305 shares during the period. Vanguard Group Inc. owned 4.35% of Taysha Gene Therapies worth $15,409,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its holdings in Taysha Gene Therapies by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock worth $820,000 after buying an additional 11,390 shares during the period. Geode Capital Management LLC boosted its holdings in Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company's stock valued at $7,163,000 after purchasing an additional 682,273 shares during the period. Wellington Management Group LLP bought a new position in Taysha Gene Therapies in the 3rd quarter valued at $931,000. Barclays PLC boosted its holdings in Taysha Gene Therapies by 356.0% in the 3rd quarter. Barclays PLC now owns 247,280 shares of the company's stock valued at $513,000 after purchasing an additional 193,046 shares during the period. Finally, State Street Corp boosted its holdings in Taysha Gene Therapies by 4.5% in the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company's stock valued at $6,973,000 after purchasing an additional 150,647 shares during the period. 77.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Needham & Company LLC reissued a "buy" rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Chardan Capital reissued a "buy" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $6.63.

Taysha Gene Therapies Trading Up 9.6 %

Taysha Gene Therapies stock traded up $0.17 during mid-day trading on Wednesday, hitting $1.95. The company's stock had a trading volume of 538,944 shares, compared to its average volume of 2,683,486. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock has a market cap of $399.86 million, a price-to-earnings ratio of 3.10 and a beta of 0.96. The business has a 50 day moving average price of $1.54 and a 200-day moving average price of $1.80. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. The business had revenue of $2.02 million during the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. As a group, analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.